Literature DB >> 15232720

Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe: a EuroSIDA study, 1994-2001.

I Yust1, Z Fox, M Burke, A Johnson, D Turner, A Mocroft, C Katlama, B Ledergerber, P Reiss, O Kirk.   

Abstract

This multicentre prospective cohort study by the EuroSIDA study group was designed to determine the factors affecting the incidence of cytomegalovirus (CMV) end-organ disease (CMVD) and the rate of survival after diagnosis in patients with AIDS during the years 1994-2001. This period includes two eras, the pre-HAART era and the HAART era, because HAART affects the natural history of HIV infection, especially with respect to opportunistic infections, including CMV infection. Clinical and laboratory data were collected from the charts of 8,556 patients in 63 AIDS clinics in Europe. A total of 707 patients had CMVD at recruitment and at follow-up: 449 with retinitis (CMVR), 190 with extraocular CMV disease (EOCMVD), and 58 with both. Of the cases of EOCMVD, 66% involved the gastrointestinal tract and 17% the central nervous system. Of patients with a CD4+ count of < or =200 mm(-3) initially, 1.8% on HAART developed CMVD within a 24-month period, as compared to 11.1% on dual therapy and 14.3% without treatment (P<0.0001). There were highly significant differences in survival according to the calendar year (P<0.0001), with mortality declining from 79% during the years 1994-1995 to 42% in 2000-2001. The incidence of death after any CMVD was 28.4 per 100 patient-years of follow-up. Median survival of CMVR patients and EOCMVD patients was 11 and 7 months, respectively, the prognosis being better among patients with gastrointestinal rather than neurological CMVD. The initiation of HAART was associated with a 37% decrease in mortality (P<0.05). Eighteen percent of all deaths were caused by EOCMVD itself. This study describes a decline in the incidence and mortality of CMVR and EOCMVD during the HAART era of the HIV epidemic. It furthermore serves as a reminder of the importance of EOCMVD as a cause of morbidity and mortality in AIDS in the pre-HAART era.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15232720     DOI: 10.1007/s10096-004-1160-2

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  40 in total

1.  Clearance of cytomegalovirus viremia after initiation of highly active antiretroviral therapy.

Authors:  G Boivin; R P LeBlanc
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

Review 2.  Cytomegalovirus pneumonia.

Authors:  N Salomon; D C Perlman
Journal:  Semin Respir Infect       Date:  1999-12

Review 3.  Overview of cytomegalovirus infections in HIV-infected patients: current therapies and future strategies.

Authors:  C S Crumpacker; M Heath-Chiozzi
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1991

4.  Increasing survival in AIDS patients with cytomegalovirus retinitis treated with combination antiretroviral therapy including HIV protease inhibitors.

Authors:  J C Walsh; C D Jones; E A Barnes; B G Gazzard; S M Mitchell
Journal:  AIDS       Date:  1998-04-16       Impact factor: 4.177

5.  Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA.

Authors:  R J Whitley; M A Jacobson; D N Friedberg; G N Holland; D A Jabs; D T Dieterich; W D Hardy; M A Polis; T A Deutsch; J Feinberg; S A Spector; S Walmsley; W L Drew; W G Powderly; P D Griffiths; C A Benson; H A Kessler
Journal:  Arch Intern Med       Date:  1998-05-11

Review 6.  AIDS and ophthalmology: a period of transition.

Authors:  D A Jabs; J G Bartlett
Journal:  Am J Ophthalmol       Date:  1997-08       Impact factor: 5.258

Review 7.  Opportunistic infections of the central nervous system during HIV-1 infection (emphasis on cytomegalovirus disease).

Authors:  E Roullet
Journal:  J Neurol       Date:  1999-04       Impact factor: 4.849

8.  Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy.

Authors:  C E O'Sullivan; W L Drew; D J McMullen; R Miner; J Y Lee; R A Kaslow; J G Lazar; M S Saag
Journal:  J Infect Dis       Date:  1999-09       Impact factor: 5.226

9.  Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis.

Authors:  S M Whitcup; E Fortin; A S Lindblad; P Griffiths; J A Metcalf; M R Robinson; J Manischewitz; B Baird; C Perry; I M Kidd; T Vrabec; R T Davey; J Falloon; R E Walker; J A Kovacs; H C Lane; R B Nussenblatt; J Smith; H Masur; M A Polis
Journal:  JAMA       Date:  1999-11-03       Impact factor: 56.272

10.  Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy.

Authors:  J R Deayton; P Wilson; C A Sabin; C C Davey; M A Johnson; V C Emery; P D Griffiths
Journal:  AIDS       Date:  2000-06-16       Impact factor: 4.177

View more
  25 in total

Review 1.  The tiers and dimensions of evasion of the type I interferon response by human cytomegalovirus.

Authors:  Lisi Amsler; Marieke Verweij; Victor R DeFilippis
Journal:  J Mol Biol       Date:  2013-09-05       Impact factor: 5.469

2.  Cytomegalovirus immune reconstitution inflammatory syndrome manifesting as sialadenitis in an HIV-infected patient.

Authors:  Virginia Sheikh; Margaret Caplan; Eleanor M P Wilson; Bhavesh Papadi; Avi Z Rosenberg; Jeannette Higgins; Brian Driscoll; Armando C Filie; Irini Sereti
Journal:  AIDS       Date:  2013-07-17       Impact factor: 4.177

Review 3.  CMV-specific immune reconstitution following allogeneic stem cell transplantation.

Authors:  Emily Blyth; Barbara Withers; Leighton Clancy; David Gottlieb
Journal:  Virulence       Date:  2016-08-09       Impact factor: 5.882

4.  Retinal detachment associated with AIDS-related cytomegalovirus retinitis: risk factors in a resource-limited setting.

Authors:  Michael Yen; Jenny Chen; Somsanguan Ausayakhun; Paradee Kunavisarut; Pornpattana Vichitvejpaisal; Sakarin Ausayakhun; Choeng Jirawison; Jessica Shantha; Gary N Holland; David Heiden; Todd P Margolis; Jeremy D Keenan
Journal:  Am J Ophthalmol       Date:  2014-10-22       Impact factor: 5.258

5.  Artemisinin-derived dimers have greatly improved anti-cytomegalovirus activity compared to artemisinin monomers.

Authors:  Ravit Arav-Boger; Ran He; Chuang-Jiun Chiou; Jianyong Liu; Lauren Woodard; Andrew Rosenthal; Lorraine Jones-Brando; Michael Forman; Gary Posner
Journal:  PLoS One       Date:  2010-04-28       Impact factor: 3.240

Review 6.  Gastrointestinal cytomegalovirus disease in the immunocompromised patient.

Authors:  Allison L Baroco; Edward C Oldfield
Journal:  Curr Gastroenterol Rep       Date:  2008-08

7.  In vitro cell-mediated immune responses of human immunodeficiency virus-infected and -uninfected individuals to whole cytomegalovirus antigens and their subunits.

Authors:  A Weinberg; J Spritzler; M Nokta; R Schrier; A Landay; D Brown; R Pollard
Journal:  Clin Vaccine Immunol       Date:  2008-06-25

8.  Cataract associated with high-dose hematopoietic colony stimulating factor, case report and literature review.

Authors:  Soad K Aljaouni; Hanadi M Aljedani
Journal:  Saudi Pharm J       Date:  2010-02-14       Impact factor: 4.330

Review 9.  Immunobiology of human cytomegalovirus: from bench to bedside.

Authors:  Tania Crough; Rajiv Khanna
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

10.  Risk of cataract among subjects with acquired immune deficiency syndrome free of ocular opportunistic infections.

Authors:  John H Kempen; Elizabeth A Sugar; Rohit Varma; James P Dunn; Murk-Hein Heinemann; Douglas A Jabs; Alice T Lyon; Richard A Lewis
Journal:  Ophthalmology       Date:  2014-08-08       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.